Stock Analysis

Top Glove Corporation Bhd Leads Trio Of Growth Stocks With High Insider Ownership

SHSE:688050
Source: Shutterstock

As global markets exhibit mixed reactions to recent economic data, investors continue to navigate through a landscape marked by fluctuating inflation rates and shifting monetary policies. In such an environment, growth companies with high insider ownership can offer unique advantages, as these insiders often have a deep commitment to the company's long-term success.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Gaming Innovation Group (OB:GIG)26.7%37.4%
Seojin SystemLtd (KOSDAQ:A178320)29.8%58.7%
KebNi (OM:KEBNI B)37.8%90.4%
Fine M-TecLTD (KOSDAQ:A441270)17.2%36.4%
Credo Technology Group Holding (NasdaqGS:CRDO)14.7%60.9%
Calliditas Therapeutics (OM:CALTX)11.6%52.9%
Adocia (ENXTPA:ADOC)11.9%63%
Vow (OB:VOW)31.8%97.7%
UTI (KOSDAQ:A179900)34.1%122.7%
EHang Holdings (NasdaqGM:EH)32.8%74.3%

Click here to see the full list of 1436 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Top Glove Corporation Bhd (KLSE:TOPGLOV)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Top Glove Corporation Bhd is a Malaysian-based company that specializes in the manufacturing, trading, and international sales of gloves, with a market capitalization of approximately MYR 9.69 billion.

Operations: The company's revenue primarily stems from the gloves manufacturing industry, generating MYR 2.16 billion.

Insider Ownership: 29.9%

Earnings Growth Forecast: 116.8% p.a.

Top Glove Corporation Bhd, a company with significant insider buying in the past three months, is poised for notable growth. Its revenue is expected to grow at 35.1% annually, outpacing the Malaysian market's 6.3% growth rate. Despite a highly volatile share price recently, Top Glove trades slightly below its estimated fair value and anticipates becoming profitable within three years—a forecast well above average market expectations. Recent board changes include new appointments enhancing governance structures as part of its strategic adjustments to foster this growth trajectory.

KLSE:TOPGLOV Ownership Breakdown as at Jul 2024
KLSE:TOPGLOV Ownership Breakdown as at Jul 2024

Eyebright Medical Technology (Beijing) (SHSE:688050)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Eyebright Medical Technology (Beijing) Co., Ltd. is a company that operates in the healthcare sector, with a market capitalization of approximately CN¥12.45 billion.

Operations: The company generates revenue primarily from its medical products segment, amounting to CN¥1.07 billion.

Insider Ownership: 21.5%

Earnings Growth Forecast: 27.2% p.a.

Eyebright Medical Technology (Beijing) demonstrates robust growth potential with its earnings expected to increase significantly, forecasted at 27.2% per year, outperforming the Chinese market's 22.2%. Despite trading 43.4% below its estimated fair value, suggesting a good investment opportunity, concerns arise from its low forecasted Return on Equity of 17.7%. Recent financials show substantial year-over-year gains with revenue rising to CNY 310.4 million and net income up to CNY 102.9 million, reflecting strong operational performance.

SHSE:688050 Earnings and Revenue Growth as at Jul 2024
SHSE:688050 Earnings and Revenue Growth as at Jul 2024

iSoftStone Information Technology (Group) (SZSE:301236)

Simply Wall St Growth Rating: ★★★★★☆

Overview: iSoftStone Information Technology (Group) Co., Ltd. is a technology service provider specializing in end-to-end solutions for various industries, with a market capitalization of approximately CN¥32.59 billion.

Operations: The company's revenue is primarily generated from Communication Equipment (CN¥7.05 billion), followed by Financial Technology (CN¥4.04 billion), Internet Service (CN¥3.29 billion), and High Technology and Manufacturing (CN¥2.37 billion).

Insider Ownership: 23.8%

Earnings Growth Forecast: 30.7% p.a.

iSoftStone Information Technology (Group) is poised for notable growth with earnings forecasted to increase by 30.7% annually, surpassing the Chinese market's average of 22.2%. Despite a robust revenue growth outlook of 24% per year, the company's profit margins have declined from last year's 5.1% to this year’s 3%. Additionally, recent corporate activities include significant amendments in governance and dividend distributions, reflecting active management engagement and potential strategic shifts aimed at enhancing long-term value.

SZSE:301236 Ownership Breakdown as at Jul 2024
SZSE:301236 Ownership Breakdown as at Jul 2024

Next Steps

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're helping make it simple.

Find out whether Eyebright Medical Technology (Beijing) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com